BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 11233059)

  • 1. Optimum screening interventions for gynecologic malignancies.
    Lea JS; Miller DS
    Tex Med; 2001 Feb; 97(2):49-55. PubMed ID: 11233059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms.
    Hall KL; Dewar MA; Perchalski J
    Prim Care; 1992 Sep; 19(3):607-20. PubMed ID: 1410066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gynecologic cancers.
    Blair AR; Casas CM
    Prim Care; 2009 Mar; 36(1):115-30, ix. PubMed ID: 19231605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian, uterine, and cervical cancer in the elderly woman.
    McGonigle KF; Lagasse LD; Karlan BY
    Clin Geriatr Med; 1993 Feb; 9(1):115-30. PubMed ID: 8443730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families.
    Chen LM; Yang KY; Little SE; Cheung MK; Caughey AB
    Obstet Gynecol; 2007 Jul; 110(1):18-25. PubMed ID: 17601891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for gynecologic malignancies: A continuing responsibility.
    Runowicz CD; Fields AL
    Surg Oncol Clin N Am; 1999 Oct; 8(4):703-23, vii. PubMed ID: 10452936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001.
    Tan W; Stehman FB; Carter RL
    Gynecol Oncol; 2009 Aug; 114(2):346-52. PubMed ID: 19411096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for gynecologic cancer.
    Campion MJ; Reid R
    Obstet Gynecol Clin North Am; 1990 Dec; 17(4):695-727. PubMed ID: 2092238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
    Hutchinson ML; Berger BM; Farber FL
    Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
    Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
    J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
    Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
    J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian intraepithelial neoplasia and ovarian cancer.
    Gershenson DM; Tortolero-Luna G; Malpica A; Baker VV; Whittaker L; Johnson E; Follen Mitchell M
    Obstet Gynecol Clin North Am; 1996 Jun; 23(2):475-543. PubMed ID: 8784888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
    Cooper CP; Saraiya M; McLean TA; Hannan J; Liesmann JM; Rose SW; Lawson HW
    J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Integrating HPV testing for primary screening?].
    Riethmuller D; Ramanah R; Pretet JL; Mougin C
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S139-51. PubMed ID: 18191912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic cancers: Part. II--risk assessment and screening.
    Lee CO
    Clin J Oncol Nurs; 2000; 4(2):73-7. PubMed ID: 11107379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Screening in gynecologic oncology].
    Ebeling K
    Zentralbl Gynakol; 1983; 105(19):1225-38. PubMed ID: 6316692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast and cervical cancer screening among Appalachian women.
    Hall HI; Uhler RJ; Coughlin SS; Miller DS
    Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):137-42. PubMed ID: 11815412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of registration of gynecologic malignant neoplasms in Shizuoka Prefecture--evaluation for one and a half years].
    Hayata T; Sumimoto K; Terao T; Kawashima Y; Nagano T
    Gan No Rinsho; 1985 Feb; 31(2):179-84. PubMed ID: 3989986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.
    Santillan A; Govan L; Zahurak ML; Diaz-Montes TP; Giuntoli RL; Bristow RE
    Gynecol Oncol; 2008 Jun; 109(3):388-93. PubMed ID: 18405946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.